◆ TICKERBASE · GLOBAL STOCK FINANCIAL DATA LIBRARY

Krystal Biotech Inc (KRYS) Net Income 2016–TTM

Name: Krystal Biotech Inc (KRYS) net income history 2016-TTM
Creator: TickerBase
License: https://creativecommons.org/licenses/by/4.0/

DATA UPDATED 2026-09-19

Krystal Biotech Inc annual net income for fiscal TTM was $241 million, an increase of 17.6% from $205 million in fiscal 2025. All figures are reported results from public filings — no estimates or projections.

KRYS Annual Net Income

Net Income (annual)	TTM → 2026-06-30	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31	2020-12-31	2019-12-31	2018-12-31	2017-12-31	2016-12-31
Net Income	$241M	$205M	$89M	$11M	($140M)	($70M)	($32M)	($19M)	($11M)	($8M)	($1M)

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

KRYS Quarterly Net Income

Net Income (quarterly)	2026-06-30	2026-03-31	2025-12-31	2025-09-30	2025-06-30	2025-03-31	2024-12-31	2024-09-30	2024-06-30
Net Income	$55M	$56M	$51M	$79M	$38M	$36M	$45M	$27M	$16M

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

Net Income at Comparable Companies

MDGL Net Income — Madrigal Pharmaceuticals Inc
CORT Net Income — Corcept Therapeutics Incorporated
AXSM Net Income — Axsome Therapeutics Inc
APGE Net Income — Apogee Therapeutics, Inc. Common Stock
KYMR Net Income — Kymera Therapeutics Inc
CYTK Net Income — Cytokinetics Inc

More KRYS metrics: Revenue · Gross Profit · Operating Income · EPS · EBITDA · Free Cash Flow · Shares Outstanding

All KRYS financial statements → Interactive KRYS charts →

About TickerBase · Data methodology & sources · Privacy · Terms

TickerBase is provided for educational and informational purposes only. It does not constitute financial, investment, tax, or legal advice, or a recommendation to buy, sell, or hold any security. No price targets are published; any per-share value shown in the valuation workbench is generated entirely from reader-supplied assumptions and is not the publisher's view of fair value. Past performance does not predict future results. Figures are approximate and drawn from public filings; one-time items are noted where identified. Do your own research and consult a licensed professional before making any investment decision. The author may or may not hold positions in the securities discussed.